147 related articles for article (PubMed ID: 38587644)
1. Targeting CXCR4/CXCL12 axis via [
Bao G; Wang Z; Liu L; Zhang B; Song S; Wang D; Cheng S; Moon ES; Roesch F; Zhao J; Yu B; Zhu X
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38587644
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [
Bao G; Zhou H; Zou S; Chen L; Zhang B; Wang Z; Moon ES; Zhao J; Roesch F; Zhu X
Mol Pharm; 2023 May; 20(5):2443-2451. PubMed ID: 37067162
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of [
Yadav MP; Ballal S; Martin M; Roesch F; Satapathy S; Moon ES; Tripathi M; Gogia A; Bal C
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):805-819. PubMed ID: 37932560
[TBL] [Abstract][Full Text] [Related]
4. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613
[TBL] [Abstract][Full Text] [Related]
5. Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics.
Martin M; Ballal S; Yadav MP; Bal C; Van Rymenant Y; De Loose J; Verhulst E; De Meester I; Van Der Veken P; Roesch F
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980775
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.
Moon ES; Ballal S; Yadav MP; Bal C; Van Rymenant Y; Stephan S; Bracke A; Van der Veken P; De Meester I; Roesch F
Am J Nucl Med Mol Imaging; 2021; 11(6):476-491. PubMed ID: 35003886
[TBL] [Abstract][Full Text] [Related]
7. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy.
Luyten K; Van Loy T; Cawthorne C; Deroose CM; Schols D; Bormans G; Cleeren F
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683912
[TBL] [Abstract][Full Text] [Related]
8. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
9. [
Ballal S; Yadav MP; Raju S; Roesch F; Martin M; Tripathi M; Bal C
Nucl Med Mol Imaging; 2024 Feb; 58(1):32-34. PubMed ID: 38261876
[TBL] [Abstract][Full Text] [Related]
10. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
11.
Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
[TBL] [Abstract][Full Text] [Related]
12. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
[TBL] [Abstract][Full Text] [Related]
13. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
[TBL] [Abstract][Full Text] [Related]
14. [
Wei Y; Zheng J; Ma L; Liu X; Xu S; Wang S; Pei J; Cheng K; Yuan S; Yu J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2761-2773. PubMed ID: 35262766
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation and pilot clinical study of [
Ge L; Fu Z; Wei Y; Shi D; Geng Y; Fan H; Zhang R; Zhang Y; Li S; Wang S; Shi H; Song G; Pan J; Cheng K; Wang L
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4025-4036. PubMed ID: 35715613
[TBL] [Abstract][Full Text] [Related]
16. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Privé BM; Boussihmad MA; Timmermans B; van Gemert WA; Peters SMB; Derks YHW; van Lith SAM; Mehra N; Nagarajah J; Heskamp S; Westdorp H
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1906-1918. PubMed ID: 36813980
[TBL] [Abstract][Full Text] [Related]
18.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
19. [
Wei Y; Cheng K; Fu Z; Zheng J; Mu Z; Zhao C; Liu X; Wang S; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1671-1681. PubMed ID: 34870727
[TBL] [Abstract][Full Text] [Related]
20. Visualization of Activated Fibroblasts in Heart Failure with Preserved Ejection Fraction with [
Sun F; Wang C; Feng H; Yu F; Zhang X; Zhang P; Du X
Mol Pharm; 2023 May; 20(5):2634-2641. PubMed ID: 37043243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
